• 1
    World Health Organization. Fact sheet N°204: hepatitis B. Available from:[Accessed November 20, 2008.
  • 2
    World Health Organization. The global burden of disease: 2004 update. Available from:[Accessed November 20, 2008.
  • 3
    Index Pharmaceuticals. Hepatitis B fact sheet. Available from:[Accessed November 20, 2008.
  • 4
    Tandon BN, Tandon A. Epidemiological trends of viral hepatitis in Asia. In: RizzettoM, PurcellRH, GerinJL, et al., eds. Viral Hepatitis and Liver Disease. Turin: Minerva Medica, 1997.
  • 5
    Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:135661.
  • 6
    Shi G, Xie YF, Liu XY, et al. Estimation of economic burden of hepatitis B. Chin Prim Health Care 2004;8:1819.
  • 7
    Hu SL. Health Economics. Shanghai: Fudan Univiersity, 2003.
  • 8
    Guan ZQ, Dong CH. Hospitalization expenditure of CHB patients with case-mix method. Chin Health Econ 2004;23:5961.
  • 9
    Chen XB, Chen HF, Lacey L, et al. Economic benefits of Lamivudine in the treatment of chronic viral hepatitis B infection. Chin Hepatol 2002;7:7981.
  • 10
    Chen W, Lu XZ, Chen HY, et al. Economic evaluation of Lamivudine in the treatment of chronic hepatitis B. Chin Hepatol 2005;10:7375.
  • 11
    Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. Lancet 2003;362:11117.
  • 12
    Kawabata K, Xu K, Carrin G. Preventing impoverishment through protection against catastrophic health expenditure. Bull World Health Organ 2002;80:612.